Stereotaxis Closes Robocath Acquisition, Merging Magnetic and Mechanical Catheter Robotics
Stereotaxis (NYSE: STXS) has completed its $20M cash-and-stock acquisition of French robotic-catheter maker Robocath, folding the R-One+ platform into its magnetic navigation stack for the full endovascular spectrum.
Key Takeaways
Stereotaxis (NYSE American: STXS) closed its acquisition of French robotic-catheter maker Robocath on July 9, 2026, paying about $20 million upfront in cash and stock plus up to $25 million in milestone earn-outs, for a total deal value of up to $45 million.
The merger folds Robocath's R-One+ platform into Stereotaxis's magnetic navigation lineup (Genesis RMN and GenesisX), creating the first robotics platform covering the full spectrum of endovascular procedures.
The two technologies are complementary: Stereotaxis steers device distal tips with computer-controlled magnetic fields, while R-One+ manipulates the proximal end bedside and is the only commercially available robotic PCI platform in Europe, with 15 systems installed globally.
Stereotaxis expects Robocath to add about $2 million in annual revenue in year one and reach breakeven by year three, with a next-gen platform in development that can simultaneously manipulate up to five interventional devices.
The deal, first disclosed in April 2026, closes amid rapid consolidation in surgical robotics alongside Medtronic's Hugo, Intuitive's da Vinci 5, and CMR Surgical's Versius Plus.
Kaan Tınmaz
Surgical robotics pioneer Stereotaxis (NYSE American: STXS) said on July 9, 2026 that it has closed its previously announced acquisition of French robotic-catheter company Robocath, folding the R-One+ platform into Stereotaxis's magnetic navigation lineup and creating the first robotics platform to cover the full spectrum of endovascular procedures.
Deal closes at $20M cash-and-stock, with milestone earn-outs
Robocath was acquired for approximately $20 million upfront in cash and Stereotaxis common stock, with up to $25 million in additional milestone-based payments tied to regulatory and commercial achievements — an all-in deal value of up to $45 million. The completion caps a definitive agreement Stereotaxis first disclosed in April 2026 and reaffirmed on its first-quarter earnings call in May.
Two robotic platforms, one endovascular stack
Stereotaxis uses computer-controlled magnetic fields to steer the distal tips of interventional devices through the heart's chambers and vasculature — technology used across electrophysiology, structural heart, and neurointerventional cases via its Genesis RMN and just-launched GenesisX systems. Robocath's R-One+, by contrast, manipulates the proximal end of interventional devices bedside and is the only commercially available robotic platform for percutaneous coronary intervention (PCI) in Europe, with 15 systems installed globally. Combined, the two platforms enable multi-device fully robotic control across coronary and neurovascular workflows.
A cardiology-and-neuro consolidation moment
The close lands as endovascular robotics consolidates fast: Medtronic's Hugo, Intuitive's da Vinci 5, and CMR Surgical's Versius Plus are all expanding indications, while humanoids are edging into live surgical rooms. Stereotaxis expects Robocath to generate about $2 million of annual revenue in year one post-close and to break even by year three, with a next-gen platform designed to simultaneously manipulate up to five interventional devices already in development.
Reporting based on coverage from GlobeNewswire, Stereotaxis IR, StockTitan, and RTTNews.
Stereotaxis paid approximately $20 million upfront in cash and common stock, with up to $25 million in additional milestone-based payments tied to regulatory and commercial achievements, for an all-in deal value of up to $45 million.
What is Robocath's R-One+ and how does it differ from Stereotaxis's technology?
R-One+ is a robotic system that manipulates the proximal end of interventional devices at the bedside and is the only commercially available robotic platform for percutaneous coronary intervention (PCI) in Europe, with 15 systems installed globally. Stereotaxis instead uses computer-controlled magnetic fields to steer the distal tips of devices, used in electrophysiology, structural heart, and neurointerventional cases.
What are the financial expectations for Robocath after the acquisition?
Stereotaxis expects Robocath to generate about $2 million in annual revenue in the first year post-close and to break even by year three.
When did the deal close and when was it first announced?
The acquisition closed on July 9, 2026. Stereotaxis first disclosed the definitive agreement in April 2026 and reaffirmed it on its first-quarter earnings call in May.
